Comparative Pharmacology
Head-to-head clinical analysis: BUTISOL SODIUM versus ESGIC PLUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTISOL SODIUM versus ESGIC PLUS.
BUTISOL SODIUM vs ESGIC-PLUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enhances GABA-A receptor activity, increasing chloride ion conductance and causing central nervous system depression.
Esgic-Plus is a combination of acetaminophen (analgesic/antipyretic via COX inhibition and central action), butalbital (barbiturate that enhances GABA-A receptor activity), and caffeine (adenosine receptor antagonist and CNS stimulant). The mechanism for treating tension headache is attributed to the synergistic effects of these components.
Oral: 50-100 mg 3-4 times daily; maximum 600 mg daily.
1-2 capsules (acetaminophen 500 mg, butalbital 50 mg, caffeine 40 mg per capsule) orally every 4 hours as needed, not exceeding 6 capsules per day.
None Documented
None Documented
Terminal elimination half-life: 40-70 hours (mean 60 h) in adults; prolonged in elderly, hepatic impairment, and neonates (up to 100 h). Clinical context: Accumulation occurs with repeated dosing.
Butalbital: 35-70 hours in adults; prolonged in hepatic/renal impairment. Acetaminophen: 2-3 hours in adults; extended in overdose (potential hepatotoxicity). Caffeine: 3-6 hours in adults; increased in pregnancy or liver disease.
Primarily hepatic metabolism (80%) with renal excretion of inactive metabolites (<30% unchanged). Less than 1% excreted in feces.
Butalbital: 60-90% renal as unchanged drug and metabolites, 10-40% fecal via biliary elimination. Acetaminophen: ~85% renal as glucuronide (45-55%), sulfate (25-35%), and cysteine conjugates (4-15%); 2-4% unchanged. Caffeine: ~85-90% renal as metabolites (1-methylxanthine, 1-methyluric acid, 1,7-dimethylxanthine); 1-3% unchanged.
Category C
Category C
Barbiturate
Barbiturate/Narcotic Combination